

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Completes if Known</b>	
				Application Number	10/573,516
				Filing Date	March 27, 2006
				First Named Inventor	Daniel Bur et al.
				Art Unit	1625
				Examiner Name	John Mabry
Sheet	1	of	2	Attorney Docket No: AC-43-US	

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>1</sup>
		WO 99/40192	06-12-1999		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>1</sup>
		AMES, R.S. et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14" <i>Nature</i> (1999), 401, pp. 282-286.			
		BERN, H.A. et al., "Neurohormones from fish tails: the caudal neurosecretory system. I. Urophysiology and the caudal neurosecretory system of fishes", <i>Recent Prog. Horm. Res.</i> , (1985), 41, pp. 533-552.			
		BREU, V. et al., In vitro characterization of Ro-46-2005, a novel synthetic non-peptide antagonist of ET <sub>A</sub> and ET <sub>B</sub> receptors., <i>FEBS Lett.</i> , (1993), 334, pp. 210-214.			
		CHEUNG, B.M. et al., "Plasma concentration of urotensin II is raised in hypertension", <i>J. Hypertens.</i> , (2004), 22, pp. 1341-1344.			
		CLOZEL, M. et al., "Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System", <i>J. Pharmacol. Exp. Ther.</i> , (2004), 311, pp. 204-212.			
		DOUGLAS, S.A., et al., "Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey", <i>Br. J. Pharmacol.</i> , (2000), 131, pp. 1262-1274.			
		DOUGLAS, S.A. et al., "Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate", <i>J. Cardiovasc. Pharmacol.</i> , (2000), 36, Suppl 1:S163-S166.			
		GARLTON, J., et al., "Central effects of urotensin-II following ICV administration in rats", <i>Psychopharmacology</i> (Berlin), (2001), 155, pp. 426-433.			
		HELLER, J. et al., "Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension", <i>J. Hepatol.</i> , (2002), 37, pp. 767-772.			
		LIU, Q. et al., "Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14", <i>Biochem. Biophys. Res. Commun.</i> , (1999), 266, pp. 174-178.			
		MALINOWSKI, M., et al., "A Convenient Preparation of 4-Pyridinamine Derivatives", <i>J. Prakt. Chem.</i> , (1986), 330, pp. 154-158.			

EXAMINER /John Mabry/ (06/05/2009)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)  
 \* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Attach with every citation designation number (document) if it is a page from a foreign language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. J.M./

Substitute for form 1449/APTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<i>Complete If Known</i>	
				Application Number	10/573,516
				Filing Date	March 27, 2006
				First Named Inventor	Daniel Bur et al.
				Art Unit	1625
				Examiner Name	John Mabry
Sheet	2	of	2	Attorney Docket No: AC-43-US	

		MORI, M. et al., "Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)", <i>Biochem. Biophys. Res. Commun.</i> , (1999), 265, pp.123-129.	
		"Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-Interscience, (1999)	
		RUSSELL, F.D., et al., "Cardiostimulant effects of urotensin-II in human heart in vitro", <i>Br. J. Pharmacol.</i> , (2001), 132, pp. 5-9.	
		SHENOUDA, S. et al., "Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma", <i>J. Histochem. Cytochem.</i> , (2002), 50, pp. 885-889.	
		SILVESTRE, R.A., et al., "Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas", <i>Horm Metab Res.</i> , (2001), 33, pp. 379-381.	
		TAKAHASHI, K. et al., "Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity b SW-13 adrenocortical carcinoma cells", <i>Peptides</i> , (2001), 22, pp. 1175-1179.	
		TAKAHASHI, K. et al., "Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II", <i>Peptides</i> , (2003), 24, pp. 301-306.	
		TOTSUNE, K. et al., "Role of urotensin II in patients on dialysis", <i>Lancet</i> , (2001), 358, pp. 810-811.	
		TOTSUNE, K. et al., "Increased plasma urotensin II levels in patients with diabetes mellitus" <i>Clin. Sci.</i> , (2003), 104, pp. 1-5.	
		TSANDIS, A. et al., "Urotensin II stimulates collagen synthesis of cardiac fibroblasts and hypertrophic signaling in cardiomyocytes via G(alpha)q- and Ras-dependent pathways", <i>J. Am. Coll. Cardiol.</i> , (2001), 37, p. 164A.	
		ZOU, Y. et al., "Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats" <i>FEBS Lett.</i> , (2001), 508, pp. 57-60.	

EXAMINER

/John Mabry/ (06/05/2009)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER Initial if reference considered, whether or not citation is in compliance with MPEP 809. Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant. If applicant desires to have citation removed, please attach and forward to the examiner. If applicant desires to have citation removed, please attach and forward to the examiner.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. J.M./